

# James Andrew McCubrey

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/491618/james-andrew-mccubrey-publications-by-citations.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

335  
papers

16,846  
citations

62  
h-index

117  
g-index

348  
ext. papers

18,714  
ext. citations

5.3  
avg, IF

6.32  
L-index

#	Paper	IF	Citations
335	Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , <b>2007</b> , 1773, 1263-84	4.9	1532
334	Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. <i>Cancer Cell</i> , <b>2006</b> , 10, 375-88	24.3	820
333	Reactive oxygen species-induced activation of the MAP kinase signaling pathways. <i>Antioxidants and Redox Signaling</i> , <b>2006</b> , 8, 1775-89	8.4	588
332	Transfer of specificity by murine alpha and beta T-cell receptor genes. <i>Nature</i> , <b>1986</b> , 320, 232-8	50.4	526
331	Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. <i>Advances in Enzyme Regulation</i> , <b>2006</b> , 46, 249-79		518
330	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. <i>Oncotarget</i> , <b>2011</b> , 2, 135-64	3.3	456
329	Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. <i>Aging</i> , <b>2011</b> , 3, 192-222	5.6	437
328	GSK-3 as potential target for therapeutic intervention in cancer. <i>Oncotarget</i> , <b>2014</b> , 5, 2881-911	3.3	332
327	Senescence-associated exosome release from human prostate cancer cells. <i>Cancer Research</i> , <b>2008</b> , 68, 7864-71	10.1	310
326	Use of an aqueous soluble tetrazolium/formazan assay to measure viability and proliferation of lymphokine-dependent cell lines. <i>Journal of Immunological Methods</i> , <b>1993</b> , 157, 233-40	2.5	262
325	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. <i>Oncotarget</i> , <b>2012</b> , 3, 1068-111	3.3	250
324	Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. <i>Oncotarget</i> , <b>2012</b> , 3, 954-87	3.3	214
323	The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. <i>Oncotarget</i> , <b>2010</b> , 1, 89-103	3.3	200
322	Current treatment strategies for inhibiting mTOR in cancer. <i>Trends in Pharmacological Sciences</i> , <b>2015</b> , 36, 124-35	13.2	195
321	Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. <i>Leukemia</i> , <b>2008</b> , 22, 708-22	10.7	194
320	Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention. <i>Oncotarget</i> , <b>2014</b> , 5, 4603-50	3.3	179
319	Cutaneous melanoma: From pathogenesis to therapy (Review). <i>International Journal of Oncology</i> , <b>2018</b> , 52, 1071-1080	4.4	164

318	Phosphatidylinositol 3Kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. <i>Cancer Research</i> , <b>2004</b> , 64, 8397-404	10.1	146
317	Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. <i>Oncotarget</i> , <b>2012</b> , 3, 236-60,3	3.3	138
316	Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. <i>Cancer Research</i> , <b>2010</b> , 70, 8097-107	10.1	136
315	PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches. <i>Cell Cycle</i> , <b>2009</b> , 8, 1352-8	4.7	133
314	Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. <i>Journal of Cellular Physiology</i> , <b>2011</b> , 226, 2762-81	7	124
313	Akt as a therapeutic target in cancer. <i>Expert Opinion on Therapeutic Targets</i> , <b>2008</b> , 12, 1139-65	6.4	114
312	Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review). <i>International Journal of Oncology</i> , <b>2003</b> , 22, 469-80	1	113
311	Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs. <i>Aging</i> , <b>2017</b> , 9, 1477-1536	5.6	112
310	Molecular mechanisms of sorafenib action in liver cancer cells. <i>Cell Cycle</i> , <b>2012</b> , 11, 2843-55	4.7	106
309	Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia. <i>Cancer Research</i> , <b>2009</b> , 69, 3520-8	10.1	106
308	A novel ring-substituted diindolylmethane, 1,1-bis[3P(5-methoxyindolyl)]-1-(p-t-butylphenyl) methane, inhibits extracellular signal-regulated kinase activation and induces apoptosis in acute myelogenous leukemia. <i>Cancer Research</i> , <b>2005</b> , 65, 2890-8	10.1	105
307	Redox regulation of the calcium/calmodulin-dependent protein kinases. <i>Journal of Biological Chemistry</i> , <b>2004</b> , 279, 44573-81	5.4	105
306	Effects of mutations in Wnt/ $\beta$ -catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity-Diverse effects on cell growth, metabolism and cancer. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , <b>2016</b> , 1863, 2942-2976	4.9	101
305	Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells. <i>Advances in Biological Regulation</i> , <b>2015</b> , 59, 65-81	6.2	98
304	Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. <i>Oncotarget</i> , <b>2012</b> , 3, 371-94	3.3	98
303	The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. <i>Cell Cycle</i> , <b>2010</b> , 9, 1781-91	4.7	97
302	The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , <b>2010</b> , 1803, 991-1002	4.9	97
301	PLC and PI3K/Akt/mTOR signalling in disease and cancer. <i>Advances in Biological Regulation</i> , <b>2015</b> , 57, 10-6	6.2	95

300	Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia. <i>Expert Opinion on Investigational Drugs</i> , <b>2009</b> , 18, 1333-49	5.9	94
299	Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells. <i>Oncogene</i> , <b>2003</b> , 22, 2478-92	9.2	92
298	mTOR as a multifunctional therapeutic target in HIV infection. <i>Drug Discovery Today</i> , <b>2011</b> , 16, 715-21	8.8	84
297	Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , <b>2016</b> , 1863, 449-463	4.9	81
296	Targeting prostate cancer based on signal transduction and cell cycle pathways. <i>Cell Cycle</i> , <b>2008</b> , 7, 1745-62	4.7	80
295	A dominant role for p53-dependent cellular senescence in radiosensitization of human prostate cancer cells. <i>Cell Cycle</i> , <b>2007</b> , 6, 595-605	4.7	80
294	Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance. <i>Clinical Cancer Research</i> , <b>2003</b> , 9, 1161-70	12.9	79
293	Analysis of BRAF mutation in primary and metastatic melanoma. <i>Cell Cycle</i> , <b>2005</b> , 4, 1382-4	4.7	78
292	The complexity of PTEN: mutation, marker and potential target for therapeutic intervention. <i>Expert Opinion on Therapeutic Targets</i> , <b>2004</b> , 8, 537-50	6.4	77
291	The Raf signal transduction cascade as a target for chemotherapeutic intervention in growth factor-responsive tumors <b>2000</b> , 88, 229-79		77
290	Roles of signaling pathways in drug resistance, cancer initiating cells and cancer progression and metastasis. <i>Advances in Biological Regulation</i> , <b>2015</b> , 57, 75-101	6.2	76
289	Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells. <i>Cancer Research</i> , <b>2008</b> , 68, 9394-403	10.1	76
288	Pancreatic cancer stem cells: association with cell surface markers, prognosis, resistance, metastasis and treatment. <i>Advances in Biological Regulation</i> , <b>2014</b> , 56, 45-50	6.2	73
287	p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3. <i>Cell Cycle</i> , <b>2012</b> , 11, 4579-88	4.7	73
286	Solubility and bioactivity of the Pseudomonas quinolone signal are increased by a Pseudomonas aeruginosa-produced surfactant. <i>Infection and Immunity</i> , <b>2005</b> , 73, 878-82	3.7	73
285	A conditionally-active form of MEK1 results in autocrine transformation of human and mouse hematopoietic cells. <i>Oncogene</i> , <b>2000</b> , 19, 526-36	9.2	73
284	The therapeutic potential of mTOR inhibitors in breast cancer. <i>British Journal of Clinical Pharmacology</i> , <b>2016</b> , 82, 1189-1212	3.8	72
283	Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells. <i>Cell Cycle</i> , <b>2011</b> , 10, 3003-15	4.7	71

282	Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review). <i>International Journal of Oncology</i> , <b>2012</b> , 40, 639-44	4.4	71
281	Roles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer. <i>Oncotarget</i> , <b>2014</b> , 5, 1576-94,3	3.3	70
280	Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy. <i>Oncotarget</i> , <b>2011</b> , 2, 538-50	3.3	69
279	Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cells. <i>Oncotarget</i> , <b>2017</b> , 8, 14221-14250	3.3	68
278	Targeting GSK3 and Associated Signaling Pathways Involved in Cancer. <i>Cells</i> , <b>2020</b> , 9,	7.9	67
277	Computational identification of microRNAs associated to both epithelial to mesenchymal transition and NGAL/MMP-9 pathways in bladder cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 72758-72766	3.3	65
276	Diverse roles of GSK-3: tumor promoter-tumor suppressor, target in cancer therapy. <i>Advances in Biological Regulation</i> , <b>2014</b> , 54, 176-96	6.2	64
275	Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance. <i>Advances in Enzyme Regulation</i> , <b>2007</b> , 47, 64-103		63
274	Expression of multidrug resistance proteins in prostate cancer is related with cell sensitivity to chemotherapeutic drugs. <i>Prostate</i> , <b>2009</b> , 69, 1448-59	4.2	62
273	Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. <i>Drug Resistance Updates</i> , <b>2007</b> , 10, 81-100	23.2	62
272	Calcium/calmodulin-dependent kinase I and calcium/calmodulin-dependent kinase kinase participate in the control of cell cycle progression in MCF-7 human breast cancer cells. <i>Cancer Research</i> , <b>2005</b> , 65, 5408-16	10.1	60
271	Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance. <i>Leukemia</i> , <b>2008</b> , 22, 2080-90	10.7	59
270	EGFR family signaling and its association with breast cancer development and resistance to chemotherapy (Review). <i>International Journal of Oncology</i> , <b>2003</b> , 22, 237-52	1	59
269	Autophagy in acute leukemias: a double-edged sword with important therapeutic implications. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , <b>2015</b> , 1853, 14-26	4.9	58
268	MMP-9 overexpression is associated with intragenic hypermethylation of MMP9 gene in melanoma. <i>Aging</i> , <b>2016</b> , 8, 933-44	5.6	57
267	Roles of NGAL and MMP-9 in the tumor microenvironment and sensitivity to targeted therapy. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , <b>2016</b> , 1863, 438-448	4.9	56
266	Potential use of rapamycin in HIV infection. <i>British Journal of Clinical Pharmacology</i> , <b>2010</b> , 70, 784-93	3.8	56
265	EGF induces cell motility and multi-drug resistance gene expression in breast cancer cells. <i>Cell Cycle</i> , <b>2006</b> , 5, 2820-6	4.7	56

264	Oleocanthol exerts antitumor effects on human liver and colon cancer cells through ROS generation. <i>International Journal of Oncology</i> , <b>2017</b> , 51, 533-544	4.4	56
263	Preclinical evaluation of the PI3K/Akt/mTOR pathway in animal models of multiple sclerosis. <i>Oncotarget</i> , <b>2018</b> , 9, 8263-8277	3.3	54
262	HIV-protease inhibitors for the treatment of cancer: Repositioning HIV protease inhibitors while developing more potent NO-hybridized derivatives?. <i>International Journal of Cancer</i> , <b>2017</b> , 140, 1713-1726	7.5	53
261	Calcium-induced ERK activation in human T lymphocytes occurs via p56(Lck) and CaM-kinase. <i>Molecular Immunology</i> , <b>2000</b> , 37, 675-83	4.3	53
260	Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels. <i>Oncotarget</i> , <b>2012</b> , 3, 811-23	3.3	53
259	Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia. <i>Journal of Cellular Physiology</i> , <b>2011</b> , 226, 822-31	7	52
258	Targeting GSK3 signaling as a potential therapy of neurodegenerative diseases and aging. <i>Expert Opinion on Therapeutic Targets</i> , <b>2018</b> , 22, 833-848	6.4	52
257	Melanoma: molecular pathogenesis and emerging target therapies (Review). <i>International Journal of Oncology</i> , <b>2009</b> , 34, 1481-9	1	51
256	A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia. <i>Oncotarget</i> , <b>2012</b> , 3, 1615-28	3.3	51
255	Emerging MEK inhibitors. <i>Expert Opinion on Emerging Drugs</i> , <b>2010</b> , 15, 203-23	3.7	50
254	Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors. <i>Current Opinion in Investigational Drugs</i> , <b>2008</b> , 9, 614-30		50
253	Participation of the calcium/calmodulin-dependent kinases in hydrogen peroxide-induced I $\kappa$ B phosphorylation in human T lymphocytes. <i>Journal of Biological Chemistry</i> , <b>2002</b> , 277, 30469-76	5.4	49
252	The AKT inhibitor MK-2206 is cytotoxic in hepatocarcinoma cells displaying hyperphosphorylated AKT-1 and synergizes with conventional chemotherapy. <i>Oncotarget</i> , <b>2013</b> , 4, 1496-506	3.3	47
251	Drug discovery targeting the mTOR pathway. <i>Clinical Science</i> , <b>2018</b> , 132, 543-568	6.5	46
250	The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms. <i>Journal of Molecular Medicine</i> , <b>2012</b> , 90, 667-79	5.5	46
249	Impact of physical exercise in cancer survivors during and after antineoplastic treatments. <i>Oncotarget</i> , <b>2018</b> , 9, 14005-14034	3.3	46
248	The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: what genetics got to do with it?. <i>Expert Opinion on Therapeutic Targets</i> , <b>2005</b> , 9, 1009-30	6.4	45
247	Integrin signaling links protein kinase C $\epsilon$ to the protein kinase B/Akt survival pathway in recurrent prostate cancer cells. <i>Oncogene</i> , <b>2004</b> , 23, 8659-72	9.2	44

246	B-Raf-dependent expression of vascular endothelial growth factor-A in Kaposi sarcoma-associated herpesvirus-infected human B cells. <i>Blood</i> , <b>2005</b> , 105, 4516-22	2.2	44
245	Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation. <i>Oncotarget</i> , <b>2014</b> , 5, 10034-47	3.3	44
244	Antitumor effects of dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, in human liver cancer cells are mediated through a reactive oxygen species-dependent mechanism. <i>Molecular Pharmacology</i> , <b>2009</b> , 76, 290-300	4.3	43
243	Insulin receptor substrate is a mediator of phosphoinositide 3-kinase activation in quiescent pancreatic cancer cells. <i>Cancer Research</i> , <b>2005</b> , 65, 9164-8	10.1	42
242	Signaling intermediates (MAPK and PI3K) as therapeutic targets in NSCLC. <i>Current Pharmaceutical Design</i> , <b>2014</b> , 20, 3944-57	3.3	42
241	Increased protein expression of the PTEN tumor suppressor in the presence of constitutively active Notch-1. <i>Cell Cycle</i> , <b>2005</b> , 4, 1389-95	4.7	40
240	NOTCH and PTEN in prostate cancer. <i>Advances in Biological Regulation</i> , <b>2014</b> , 56, 51-65	6.2	39
239	PKR regulates B56(alpha)-mediated BCL2 phosphatase activity in acute lymphoblastic leukemia-derived REH cells. <i>Journal of Biological Chemistry</i> , <b>2008</b> , 283, 35474-85	5.4	39
238	Molecular pathways leading to oxidative stress-induced phosphorylation of Akt. <i>Antioxidants and Redox Signaling</i> , <b>2006</b> , 8, 1749-56	8.4	39
237	Advances in targeting signal transduction pathways. <i>Oncotarget</i> , <b>2012</b> , 3, 1505-21	3.3	39
236	The mechanism of contribution of integrin linked kinase (ILK) to epithelial-mesenchymal transition (EMT). <i>Advances in Enzyme Regulation</i> , <b>2011</b> , 51, 195-207		38
235	Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells. <i>Advances in Enzyme Regulation</i> , <b>2010</b> , 50, 285-307		38
234	Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells. <i>Oncotarget</i> , <b>2011</b> , 2, 610-26	3.3	38
233	NOTCH3 expression is linked to breast cancer seeding and distant metastasis. <i>Breast Cancer Research</i> , <b>2018</b> , 20, 105	8.3	38
232	Analysis of the B-RafV600E mutation in cutaneous melanoma patients with occupational sun exposure. <i>Oncology Reports</i> , <b>2014</b> , 31, 1079-82	3.5	37
231	Emerging targeted therapies for melanoma treatment (review). <i>International Journal of Oncology</i> , <b>2014</b> , 45, 516-24	4.4	37
230	Novel combination of celecoxib and proteasome inhibitor MG132 provides synergistic antiproliferative and proapoptotic effects in human liver tumor cells. <i>Cell Cycle</i> , <b>2010</b> , 9, 1399-410	4.7	37
229	Computational Modeling of PI3K/AKT and MAPK Signaling Pathways in Melanoma Cancer. <i>PLoS ONE</i> , <b>2016</b> , 11, e0152104	3.7	37

228	PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer. <i>Scientific Reports</i> , <b>2017</b> , 7, 43013	4.9	36
227	Inhibition of GSK-3 $\beta$ activity can result in drug and hormonal resistance and alter sensitivity to targeted therapy in MCF-7 breast cancer cells. <i>Cell Cycle</i> , <b>2014</b> , 13, 820-33	4.7	36
226	Targeting the cancer initiating cell: the ultimate target for cancer therapy. <i>Current Pharmaceutical Design</i> , <b>2012</b> , 18, 1784-95	3.3	36
225	In vitro and in vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells. <i>Cell Cycle</i> , <b>2011</b> , 10, 492-9	4.7	36
224	Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs. <i>Cell Cycle</i> , <b>2010</b> , 9, 1629-38	4.7	36
223	The role of downstream signaling pathways of the epidermal growth factor receptor for Artesunate $\beta$ activity in cancer cells. <i>Current Cancer Drug Targets</i> , <b>2009</b> , 9, 72-80	2.8	36
222	Activation of the calcium/calmodulin-dependent protein kinases as a consequence of oxidative stress. <i>Antioxidants and Redox Signaling</i> , <b>2006</b> , 8, 1807-17	8.4	36
221	Raf promotes human herpesvirus-8 (HHV-8/KSHV) infection. <i>Oncogene</i> , <b>2004</b> , 23, 5227-41	9.2	36
220	P21(Cip1) induced by Raf is associated with increased Cdk4 activity in hematopoietic cells. <i>Oncogene</i> , <b>2001</b> , 20, 4354-64	9.2	36
219	Inhibition of Cdk2 kinase activity selectively targets the CD44+/CD24 <sup>low</sup> /Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells. <i>International Journal of Oncology</i> , <b>2014</b> , 45, 1193-9	4.4	35
218	Cardiovascular disease-related miRNAs expression: potential role as biomarkers and effects of training exercise. <i>Oncotarget</i> , <b>2018</b> , 9, 17238-17254	3.3	35
217	Metformin influences drug sensitivity in pancreatic cancer cells. <i>Advances in Biological Regulation</i> , <b>2018</b> , 68, 13-30	6.2	34
216	Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies. <i>Journal of Molecular Medicine</i> , <b>2012</b> , 90, 1133-44	5.5	34
215	Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies. <i>Expert Opinion on Therapeutic Targets</i> , <b>2012</b> , 16, 729-42	6.4	34
214	PI3K activation is associated with intracellular sodium/iodide symporter protein expression in breast cancer. <i>BMC Cancer</i> , <b>2007</b> , 7, 137	4.8	34
213	The antitumor properties of a nontoxic, nitric oxide-modified version of saquinavir are independent of Akt. <i>Molecular Cancer Therapeutics</i> , <b>2009</b> , 8, 1169-78	6.1	33
212	The emerging role of the phosphatidylinositol 3-kinase/ akt/mammalian target of rapamycin signaling network in cancer stem cell biology. <i>Cancers</i> , <b>2010</b> , 2, 1576-96	6.6	32
211	Activity of the selective IB kinase inhibitor BMS-345541 against T-cell acute lymphoblastic leukemia: involvement of FOXO3a. <i>Cell Cycle</i> , <b>2012</b> , 11, 2467-75	4.7	32



210	Detection of BRAF gene mutation in primary choroidal melanoma tissue. <i>Cancer Biology and Therapy</i> , <b>2006</b> , 5, 225-7	4.6	32
209	Regulation of GSK-3 activity by curcumin, berberine and resveratrol: Potential effects on multiple diseases. <i>Advances in Biological Regulation</i> , <b>2017</b> , 65, 77-88	6.2	31
208	Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan-2-amine (A443654) in T-cell acute lymphoblastic leukemia. <i>Molecular Pharmacology</i> , <b>2008</b> , 74, 884-95	4.3	31
207	The novel NF- $\kappa$ B inhibitor DHMEQ synergizes with celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism. <i>Cancer Letters</i> , <b>2012</b> , 322, 35-44	9.9	30
206	Emerging Raf inhibitors. <i>Expert Opinion on Emerging Drugs</i> , <b>2009</b> , 14, 633-48	3.7	30
205	Akt inactivates ERK causing decreased response to chemotherapeutic drugs in advanced CaP cells. <i>Cell Cycle</i> , <b>2008</b> , 7, 631-6	4.7	30
204	Assessment of the effect of sphingosine kinase inhibitors on apoptosis, unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; indications for novel therapeutics. <i>Oncotarget</i> , <b>2014</b> , 5, 7886-901	3.3	30
203	Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia. <i>Oncotarget</i> , <b>2015</b> , 6, 32089-103	3.3	30
202	Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF- $\kappa$ B. <i>Oncotarget</i> , <b>2016</b> , 7, 1323-40	3.3	30
201	Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy. <i>Current Pharmaceutical Design</i> , <b>2016</b> , 22, 2358-88	3.3	30
200	Nuclear phospholipase C $\beta$ signaling, epigenetics and treatments in MDS. <i>Advances in Biological Regulation</i> , <b>2013</b> , 53, 2-7	6.2	29
199	Synergy between PI3K/Akt and Raf/MEK/ERK Pathways in IGF-1R Mediated Cell Cycle Progression and Prevention of Apoptosis in Hematopoietic Cells. <i>Cell Cycle</i> , <b>2004</b> , 3, 370-377	4.7	29
198	The phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin signaling network and the control of normal myelopoiesis. <i>Histology and Histopathology</i> , <b>2010</b> , 25, 669-80	1.4	29
197	PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors. <i>Oncotarget</i> , <b>2015</b> , 6, 10399-414	3.3	29
196	Nuclear PI-PLC $\beta$ : an appraisal on targets and pathology. <i>Advances in Biological Regulation</i> , <b>2014</b> , 54, 2-11	6.2	28
195	Targeting breast cancer initiating cells: advances in breast cancer research and therapy. <i>Advances in Biological Regulation</i> , <b>2014</b> , 56, 81-107	6.2	28
194	Roles of TP53 in determining therapeutic sensitivity, growth, cellular senescence, invasion and metastasis. <i>Advances in Biological Regulation</i> , <b>2017</b> , 63, 32-48	6.2	28
193	Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia. <i>Cell Cycle</i> , <b>2014</b> , 13, 2237-47	4.7	28

192	Nuclear phosphoinositides and their roles in cell biology and disease. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , <b>2011</b> , 46, 436-57	8.7	28
191	The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells. <i>Oncotarget</i> , <b>2015</b> , 6, 17147-60	3.3	28
190	PLC- $\eta$ and cell differentiation: An insight into myogenesis and osteogenesis. <i>Advances in Biological Regulation</i> , <b>2017</b> , 63, 1-5	6.2	27
189	Pivotal roles of glycogen synthase-3 in hepatocellular carcinoma. <i>Advances in Biological Regulation</i> , <b>2017</b> , 65, 59-76	6.2	27
188	Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy. <i>Cell Cycle</i> , <b>2010</b> , 9, 1839-46	4.7	27
187	Calcium/calmodulin-dependent protein kinases as potential targets in cancer therapy. <i>Expert Opinion on Therapeutic Targets</i> , <b>2005</b> , 9, 791-808	6.4	27
186	Novel roles of androgen receptor, epidermal growth factor receptor, TP53, regulatory RNAs, NF-kappa-B, chromosomal translocations, neutrophil associated gelatinase, and matrix metalloproteinase-9 in prostate cancer and prostate cancer stem cells. <i>Advances in Biological Regulation</i> , <b>2016</b> , 60, 64-87	6.2	26
185	RAS/RAF/MEK/ERK, PI3K/PTEN/AKT/mTORC1 and TP53 pathways and regulatory miRs as therapeutic targets in hepatocellular carcinoma. <i>Expert Opinion on Therapeutic Targets</i> , <b>2019</b> , 23, 915-929	6.4	26
184	Malignant melanoma in elderly patients: biological, surgical and medical issues. <i>Expert Review of Anticancer Therapy</i> , <b>2015</b> , 15, 101-8	3.5	26
183	COX-2-dependent and COX-2-independent mode of action of celecoxib in human liver cancer cells. <i>OMICS A Journal of Integrative Biology</i> , <b>2011</b> , 15, 383-92	3.8	26
182	Influence of physical exercise on microRNAs in skeletal muscle regeneration, aging and diseases. <i>Oncotarget</i> , <b>2018</b> , 9, 17220-17237	3.3	26
181	Novel combination of sorafenib and celecoxib provides synergistic anti-proliferative and pro-apoptotic effects in human liver cancer cells. <i>PLoS ONE</i> , <b>2013</b> , 8, e65569	3.7	25
180	Characterization of human melanoma cell lines and melanocytes by proteome analysis. <i>Cell Cycle</i> , <b>2011</b> , 10, 2924-36	4.7	25
179	Inhibition of the CaM-kinases augments cell death in response to oxygen radicals and oxygen radical inducing cancer therapies in MCF-7 human breast cancer cells. <i>Cancer Biology and Therapy</i> , <b>2006</b> , 5, 1022-30	4.6	25
178	Elevated Serum Levels of Osteopontin in HCV-Associated Lymphoproliferative Disorders. <i>Cancer Biology and Therapy</i> , <b>2005</b> , 4, 1192-4	4.6	25
177	Conditional EGFR promotes cell cycle progression and prevention of apoptosis in the absence of autocrine cytokines. <i>Cell Cycle</i> , <b>2005</b> , 4, 822-30	4.7	25
176	Targeting the Raf kinase cascade in cancer therapy--novel molecular targets and therapeutic strategies. <i>Expert Opinion on Therapeutic Targets</i> , <b>2002</b> , 6, 659-78	6.4	25
175	Genetic interactions in induction of endogenous murine leukemia virus from low leukemic mice. <i>Cell</i> , <b>1982</b> , 28, 881-8	56.2	25

174	Abilities of berberine and chemically modified berberines to inhibit proliferation of pancreatic cancer cells. <i>Advances in Biological Regulation</i> , <b>2019</b> , 71, 172-182	6.2	25
173	Nuclear inositide signaling and cell cycle. <i>Advances in Biological Regulation</i> , <b>2018</b> , 67, 1-6	6.2	25
172	The NO-modified HIV protease inhibitor as a valuable drug for hematological malignancies: Role of p70S6K. <i>Leukemia Research</i> , <b>2015</b> , 39, 1088-95	2.7	24
171	Nuclear Phosphatidylinositol Signaling: Focus on Phosphatidylinositol Phosphate Kinases and Phospholipases C. <i>Journal of Cellular Physiology</i> , <b>2016</b> , 231, 1645-55	7	24
170	Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,	6.3	24
169	Therapeutic potential of nitric oxide-modified drugs in colon cancer cells. <i>Molecular Pharmacology</i> , <b>2012</b> , 82, 700-10	4.3	24
168	Identification of a functional nuclear export sequence in diacylglycerol kinase-zeta. <i>Cell Cycle</i> , <b>2010</b> , 9, 384-8	4.7	24
167	Raf-induced vascular endothelial growth factor augments Kaposi's sarcoma-associated herpesvirus infection. <i>Journal of Virology</i> , <b>2004</b> , 78, 13381-90	6.6	24
166	Targeting the phosphatidylinositol 3-kinase/Akt/mechanistic target of rapamycin signaling pathway in B-lineage acute lymphoblastic leukemia: An update. <i>Journal of Cellular Physiology</i> , <b>2018</b> , 233, 6440-6454	7.4	23
165	K562 cell proliferation is modulated by PLC $\beta$ through a PKC $\beta$ mediated pathway. <i>Cell Cycle</i> , <b>2013</b> , 12, 1713-21	4.7	23
164	Signaling through 3',5'-cyclic adenosine monophosphate and phosphoinositide-3 kinase induces sodium/iodide symporter expression in breast cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2004</b> , 89, 5196-203	5.6	23
163	Aurora-A mitotic kinase induces endocrine resistance through down-regulation of ER $\alpha$ expression in initially ER $\alpha$ breast cancer cells. <i>PLoS ONE</i> , <b>2014</b> , 9, e96995	3.7	23
162	New landscapes and horizons in hepatocellular carcinoma therapy. <i>Aging</i> , <b>2020</b> , 12, 3053-3094	5.6	23
161	Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia. <i>Oncotarget</i> , <b>2015</b> , 6, 6597-610	3.3	23
160	Nuclear Inositide Signaling Via Phospholipase C. <i>Journal of Cellular Biochemistry</i> , <b>2017</b> , 118, 1969-1978	4.7	22
159	Tumor microenvironment in diffuse large B-cell lymphoma: Matrix metalloproteinases activation is mediated by osteopontin overexpression. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , <b>2016</b> , 1863, 483-489	4.9	22
158	Absence of BRAF gene mutation in non-melanoma skin tumors. <i>Cell Cycle</i> , <b>2006</b> , 5, 968-70	4.7	22
157	Vascular endothelial growth factor augments human herpesvirus-8 (HHV-8/KSHV) infection. <i>Cancer Biology and Therapy</i> , <b>2004</b> , 3, 876-81	4.6	22

156	The effects of beta-estradiol on Raf activity, cell cycle progression and growth factor synthesis in the MCF-7 breast cancer cell line. <i>Cancer Biology and Therapy</i> , <b>2002</b> , 1, 256-62	4.6	22
155	Targeting HSP90 with the small molecule inhibitor AUY922 (luminespib) as a treatment strategy against hepatocellular carcinoma. <i>International Journal of Cancer</i> , <b>2019</b> , 144, 2613-2624	7.5	22
154	Effects of berberine, curcumin, resveratrol alone and in combination with chemotherapeutic drugs and signal transduction inhibitors on cancer cells-Power of nutraceuticals. <i>Advances in Biological Regulation</i> , <b>2018</b> , 67, 190-211	6.2	21
153	A PTEN inhibitor displays preclinical activity against hepatocarcinoma cells. <i>Cell Cycle</i> , <b>2016</b> , 15, 573-83	4.7	21
152	Raf-1 oncogenic signaling is linked to activation of mesenchymal to epithelial transition pathway in metastatic breast cancer cells. <i>International Journal of Oncology</i> , <b>2012</b> , 40, 1858-64	4.4	21
151	Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine. <i>Cell Cycle</i> , <b>2012</b> , 11, 4447-61	4.7	21
150	Molecular targeted therapy in melanoma: a way to reverse resistance to conventional drugs. <i>Current Drug Delivery</i> , <b>2012</b> , 9, 17-29	3.2	21
149	Raf-Induced Cell Cycle Progression in Human TF-1 Hematopoietic Cells. <i>Cell Cycle</i> , <b>2002</b> , 1, 218-224	4.7	21
148	Cytotoxic activity of the novel small molecule AKT inhibitor SC66 in hepatocellular carcinoma cells. <i>Oncotarget</i> , <b>2015</b> , 6, 1707-22	3.3	21
147	Recent progress in genetics of aging, senescence and longevity: focusing on cancer-related genes. <i>Oncotarget</i> , <b>2012</b> , 3, 1522-32	3.3	21
146	BRAF mutations in papillary thyroid carcinoma and emerging targeted therapies (review). <i>Molecular Medicine Reports</i> , <b>2012</b> , 6, 687-94	2.9	20
145	Revisiting nuclear phospholipase C signalling in MDS. <i>Advances in Biological Regulation</i> , <b>2012</b> , 52, 2-6	6.2	20
144	Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy. <i>Advances in Enzyme Regulation</i> , <b>2008</b> , 48, 113-35		20
143	Analysis of TIMP-1 gene polymorphisms in Italian sclerodermic patients. <i>Journal of Clinical Laboratory Analysis</i> , <b>2006</b> , 20, 173-6	3	20
142	Selective killing of adriamycin-resistant (G2 checkpoint-deficient and MRP1-expressing) cancer cells by docetaxel. <i>Cancer Research</i> , <b>2005</b> , 65, 4401-7	10.1	20
141	Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals. <i>Advances in Biological Regulation</i> , <b>2018</b> , 69, 16-34	6.2	20
140	Modulation of nuclear PI-PLCbeta1 during cell differentiation. <i>Advances in Biological Regulation</i> , <b>2016</b> , 60, 1-5	6.2	19
139	Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (review). <i>International Journal of Oncology</i> , <b>2014</b> , 45, 909-18	4.4	19

138	Effects of a conditionally active v-ErbB and an EGF-R inhibitor on transformation of NIH-3T3 cells and abrogation of cytokine dependency of hematopoietic cells. <i>Oncogene</i> , <b>2004</b> , 23, 7810-20	9.2	19
137	Effects of deregulated RAF and MEK1 expression on the cytokine-dependency of hematopoietic cells. <i>Advances in Enzyme Regulation</i> , <b>2000</b> , 40, 305-37		19
136	Nuclear Nox4 interaction with prelamin A is associated with nuclear redox control of stem cell aging. <i>Aging</i> , <b>2018</b> , 10, 2911-2934	5.6	19
135	Cancer therapy and treatments during COVID-19 era. <i>Advances in Biological Regulation</i> , <b>2020</b> , 77, 100739	6.2	19
134	Ability of the activated PI3K/Akt oncoproteins to synergize with MEK1 and induce cell cycle progression and abrogate the cytokine-dependence of hematopoietic cells. <i>Cell Cycle</i> , <b>2004</b> , 3, 503-12	4.7	19
133	PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: new options for targeted therapy. <i>Advances in Biological Regulation</i> , <b>2012</b> , 52, 214-27	6.2	18
132	Recent discoveries in the cycling, growing and aging of the p53 field. <i>Aging</i> , <b>2012</b> , 4, 887-93	5.6	18
131	Targeting the PI3K and MAPK pathways to treat Kaposi's sarcoma-associated herpes virus infection and pathogenesis. <i>Expert Opinion on Therapeutic Targets</i> , <b>2007</b> , 11, 589-99	6.4	18
130	Synergistic effects of pi3k/akt on abrogation of cytokine-dependency induced by oncogenic raf. <i>Advances in Enzyme Regulation</i> , <b>2001</b> , 41, 289-323		18
129	PLC-beta 1 regulates the expression of miR-210 during mithramycin-mediated erythroid differentiation in K562 cells. <i>Oncotarget</i> , <b>2014</b> , 5, 4222-31	3.3	18
128	Selective Activation of Nuclear PI-PLCbeta1 During Normal and Therapy-Related Differentiation. <i>Current Pharmaceutical Design</i> , <b>2016</b> , 22, 2345-8	3.3	18
127	The Key Roles of PTEN in T-Cell Acute Lymphoblastic Leukemia Development, Progression, and Therapeutic Response. <i>Cancers</i> , <b>2019</b> , 11,	6.6	17
126	Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes. <i>Leukemia</i> , <b>2019</b> , 33, 2276-2290	10.7	17
125	The Unfolded Protein Response: A Novel Therapeutic Target in Acute Leukemias. <i>Cancers</i> , <b>2020</b> , 12,	6.6	17
124	Molecular targeting of the Aurora-A/SMAD5 oncogenic axis restores chemosensitivity in human breast cancer cells. <i>Oncotarget</i> , <b>2017</b> , 8, 91803-91816	3.3	17
123	Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia. <i>Oncotarget</i> , <b>2016</b> , 7, 79842-79853	3.3	17
122	Exploiting p53 status to enhance effectiveness of chemotherapy by lowering associated toxicity. <i>Oncotarget</i> , <b>2011</b> , 2, 109-12	3.3	17
121	The Role of GSK-3 in Cancer Immunotherapy: GSK-3 Inhibitors as a New Frontier in Cancer Treatment. <i>Cells</i> , <b>2020</b> , 9,	7.9	16

120	Nuclear translocation of PKC- $\zeta$ s associated with cell cycle arrest and erythroid differentiation in myelodysplastic syndromes (MDSs). <i>FASEB Journal</i> , <b>2018</b> , 32, 681-692	0.9	16
119	Roles of p53, NF- $\kappa$ B and the androgen receptor in controlling NGAL expression in prostate cancer cell lines. <i>Advances in Biological Regulation</i> , <b>2018</b> , 69, 43-62	6.2	16
118	Inhibition of Cdk2 activity decreases Aurora-A kinase centrosomal localization and prevents centrosome amplification in breast cancer cells. <i>Oncology Reports</i> , <b>2013</b> , 29, 1785-8	3.5	16
117	Development of a conditional in vivo model to evaluate the efficacy of small molecule inhibitors for the treatment of Raf-transformed hematopoietic cells. <i>Cancer Research</i> , <b>2005</b> , 65, 9962-70	10.1	16
116	A novel DAG-dependent mechanism links PKC $\zeta$ and Cyclin B1 regulating cell cycle progression. <i>Oncotarget</i> , <b>2014</b> , 5, 11526-40	3.3	16
115	Nuclear phospholipase C isoenzyme imbalance leads to pathologies in brain, hematologic, neuromuscular, and fertility disorders. <i>Journal of Lipid Research</i> , <b>2019</b> , 60, 312-317	6.3	16
114	Abilities of berberine and chemically modified berberines to interact with metformin and inhibit proliferation of pancreatic cancer cells. <i>Advances in Biological Regulation</i> , <b>2019</b> , 73, 100633	6.2	15
113	OSU-03012 in the treatment of glioblastoma. <i>Molecular Pharmacology</i> , <b>2006</b> , 70, 437-9	4.3	15
112	Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells. <i>Oncotarget</i> , <b>2017</b> , 8, 76525-76557	3.3	15
111	Comparative study of rapamycin and temsirolimus demonstrates superimposable anti-tumour potency on prostate cancer cells. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2013</b> , 112, 63-9	3.1	14
110	Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment. <i>Advances in Biological Regulation</i> , <b>2013</b> , 53, 146-55	6.2	14
109	Clusterin enhances AKT2-mediated motility of normal and cancer prostate cells through a PTEN and PHLPP1 circuit. <i>Journal of Cellular Physiology</i> , <b>2019</b> , 234, 11188-11199	7	14
108	Novel approaches to target cancer initiating cells-eliminating the root of the cancer. <i>Advances in Biological Regulation</i> , <b>2012</b> , 52, 249-64	6.2	13
107	Targeting the cancer initiating cell: the Achilles Pheel of cancer. <i>Advances in Enzyme Regulation</i> , <b>2011</b> , 51, 152-62		13
106	Effects of ectopic expression of NGAL on doxorubicin sensitivity. <i>Oncotarget</i> , <b>2012</b> , 3, 1236-45	3.3	13
105	Diagnostic value of neutrophil gelatinase-associated lipocalin/matrix metalloproteinase-9 pathway in transitional cell carcinoma of the bladder. <i>Tumor Biology</i> , <b>2016</b> , 37, 9855-63	2.9	12
104	Inositide-dependent signaling pathways as new therapeutic targets in myelodysplastic syndromes. <i>Expert Opinion on Therapeutic Targets</i> , <b>2016</b> , 20, 677-87	6.4	12
103	Saquinavir-NO-targeted S6 protein mediates sensitivity of androgen-dependent prostate cancer cells to TRAIL. <i>Cell Cycle</i> , <b>2012</b> , 11, 1174-82	4.7	12

102	Radiosensitization of prostate cancer by priming the wild-type p53-dependent cellular senescence pathway. <i>Cancer Biology and Therapy</i> , <b>2007</b> , 6, 1165-70	4.6	12
101	Phospholipase C- $\beta$ interacts with cyclin E in adipose- derived stem cells osteogenic differentiation. <i>Advances in Biological Regulation</i> , <b>2019</b> , 71, 1-9	6.2	12
100	Modulation of Raf/MEK/ERK kinase activity does not affect the chemoresistance profile of advanced prostate cancer cells. <i>International Journal of Oncology</i> , <b>2005</b> , 26, 1637-44	1	12
99	Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia. <i>Expert Opinion on Therapeutic Targets</i> , <b>2013</b> , 17, 921-36	6.4	11
98	EGFR family signaling and its association with breast cancer development and resistance to chemotherapy (Review) <b>2003</b> , 22, 237		11
97	Ability of the Activated PI3K/Akt Oncoproteins to Synergize with MEK1 and Induce Cell Cycle Progression and Abrogate the Cytokine-Dependence of Hematopoietic Cells. <i>Cell Cycle</i> , <b>2004</b> , 3, 501-510	4.7	11
96	Transformation of B and non-B cell lines with the 2,4,6-trinitrophenyl (TNP)-specific immunoglobulin genes. <i>European Journal of Immunology</i> , <b>1985</b> , 15, 1117-24	6.1	11
95	TP53/miR-34a-associated signaling targets expression in human pancreatic cancer. <i>Aging</i> , <b>2020</b> , 12, 2777-2797	5.7	11
94	Influences of TP53 and the anti-aging DDR1 receptor in controlling Raf/MEK/ERK and PI3K/Akt expression and chemotherapeutic drug sensitivity in prostate cancer cell lines. <i>Aging</i> , <b>2020</b> , 12, 10194-10210	5.6	11
93	Healthy CD4+ T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia. <i>Oncotarget</i> , <b>2016</b> , 7, 55690-55703	3.3	11
92	Raf-induced cell cycle progression in human TF-1 hematopoietic cells. <i>Cell Cycle</i> , <b>2002</b> , 1, 220-6	4.7	11
91	Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , <b>2019</b> , 1866, 1322-1337	4.9	10
90	Dimeric and tetrameric forms of muscle fructose-1,6-bisphosphatase play different roles in the cell. <i>Oncotarget</i> , <b>2017</b> , 8, 115420-115433	3.3	10
89	Induction of caspase-independent apoptotic-like cell death of mouse mammary tumor TA3Ha cells in vitro and reduction of their lethality in vivo by the novel chemotherapeutic agent GIT-27NO. <i>Free Radical Biology and Medicine</i> , <b>2010</b> , 48, 1090-9	7.8	10
88	Inhibition of CREB transcriptional activity in human T lymphocytes by oxidative stress. <i>Free Radical Biology and Medicine</i> , <b>2005</b> , 38, 1653-61	7.8	10
87	Biology of Kaposi's sarcoma-associated herpesvirus. <i>Frontiers in Bioscience - Landmark</i> , <b>2005</b> , 10, 2882-91	2.8	10
86	Structure and expression of the T cell receptor gamma locus in pre-B and early hemopoietic cells. <i>European Journal of Immunology</i> , <b>1989</b> , 19, 2303-8	6.1	10
85	PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines. <i>Oncotarget</i> , <b>2017</b> , 8, 23213-23227	3.3	10

84	Signaling Intermediates (PI3K/PTEN/AKT/mTOR and RAF/MEK/ERK Pathways) as Therapeutic Targets for Anti-Cancer and Anti-Angiogenesis Treatments. <i>Current Signal Transduction Therapy</i> , <b>2009</b> , 4, 130-143	0.8	10
83	Recent Progress in Discovering the Role of Carotenoids and Metabolites in Prostatic Physiology and Pathology-A Review-Part II: Carotenoids in the Human Studies. <i>Antioxidants</i> , <b>2021</b> , 10,	7.1	10
82	miRNAs and their roles in KSHV pathogenesis. <i>Virus Research</i> , <b>2019</b> , 266, 15-24	6.4	9
81	Effects of endogenous epidermal growth factor receptor signaling on DNA synthesis and ERK activation in a cytokine-dependent hematopoietic cell line. <i>Cell Cycle</i> , <b>2005</b> , 4, 818-21	4.7	9
80	Cigarette smoke concentrate inhibits Kaposi's sarcoma-associated herpesvirus infection. <i>Virus Research</i> , <b>2005</b> , 114, 172-6	6.4	9
79	Docetaxel Cytotoxicity is Enhanced by Inhibition of the Raf/MEK/ERK Signal Transduction Pathway. <i>Cancer Biology and Therapy</i> , <b>2003</b> , 2, 676-677	4.6	9
78	Recent progress in targeting cancer. <i>Aging</i> , <b>2011</b> , 3, 1154-62	5.6	9
77	Therapeutic resistance in breast cancer cells can result from deregulated EGFR signaling. <i>Advances in Biological Regulation</i> , <b>2020</b> , 78, 100758	6.2	9
76	The Reverse Warburg Effect is Associated with Fbp2-Dependent Hif1 $\alpha$ Regulation in Cancer Cells Stimulated by Fibroblasts. <i>Cells</i> , <b>2020</b> , 9,	7.9	8
75	The cyclin-dependent kinase inhibitor roscovitine and the nucleoside analog sangivamycin induce apoptosis in caspase-3 deficient breast cancer cells independent of caspase mediated P-glycoprotein cleavage: implications for therapy of drug resistant breast cancers. <i>Cell Cycle</i> , <b>2009</b> , 8, 1421-5	4.7	8
74	Nuclear PI-PLC $\beta$ and myelodysplastic syndromes: genetics and epigenetics. <i>Current Pharmaceutical Design</i> , <b>2012</b> , 18, 1751-4	3.3	8
73	GSK-3 $\beta$ is a critical mediator of tetrandrine induced cell cycle arrest and cytotoxicity. <i>Cancer Biology and Therapy</i> , <b>2008</b> , 7, 1079	4.6	8
72	Models of energy in the human Jurkat T cell line. <i>Assay and Drug Development Technologies</i> , <b>2003</b> , 1, 537-44	4.4	8
71	Drug-resistance in doxorubicin-resistant FL5.12 hematopoietic cells: elevated MDR1, drug efflux and side-population positive and decreased BCL2-family member expression. <i>Oncotarget</i> , <b>2017</b> , 8, 113033-113033	3.3	8
70	Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticals. <i>Advances in Biological Regulation</i> , <b>2019</b> , 72, 22-40	6.2	7
69	Activated EGFR promotes the survival of B-lineage acute leukemia in the absence of stromal cells. <i>Cell Cycle</i> , <b>2005</b> , 4, 483-7	4.7	7
68	Cell-to-cell lactate shuttle operates in heart and is important in age-related heart failure. <i>Aging</i> , <b>2020</b> , 12, 3388-3406	5.6	7
67	Insulin/IGF1-PI3K-dependent nucleolar localization of a glycolytic enzyme--phosphoglycerate mutase 2, is necessary for proper structure of nucleolus and RNA synthesis. <i>Oncotarget</i> , <b>2015</b> , 6, 17237-50	3.3	7



66	Abilities of Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and alter the proliferation of pancreatic cancer cells. <i>Advances in Biological Regulation</i> , <b>2020</b> , 75, 100672	6.2	7
65	GSK-3 Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals. <i>Cells</i> , <b>2021</b> , 10,	7.9	7
64	B-raf and insulin synergistically prevent apoptosis and induce cell cycle progression in hematopoietic cells. <i>Cell Cycle</i> , <b>2004</b> , 3, 189-96	4.7	7
63	Pharmacological breast cancer therapy (review). <i>International Journal of Oncology</i> , <b>2005</b> , 27, 1341-4	1	7
62	Quantitative phosphoproteome analysis of embryonic stem cell differentiation toward blood. <i>Oncotarget</i> , <b>2015</b> , 6, 10924-39	3.3	6
61	Antitumor Mechanism of the Essential Oils from Two Succulent Plants in Multidrug Resistance Leukemia Cell. <i>Pharmaceuticals</i> , <b>2019</b> , 12,	5.2	5
60	GSK-3 and miRs: Master regulators of therapeutic sensitivity of cancer cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , <b>2020</b> , 1867, 118770	4.9	5
59	The PI3K/Akt/mTOR pathway: A potential pharmacological target in COVID-19. <i>Drug Discovery Today</i> , <b>2021</b> ,	8.8	5
58	Recent Progress in Discovering the Role of Carotenoids and Their Metabolites in Prostatic Physiology and Pathology with a Focus on Prostate Cancer-A Review-Part I: Molecular Mechanisms of Carotenoid Action. <i>Antioxidants</i> , <b>2021</b> , 10,	7.1	5
57	GSK3 and miRNA in neural tissue: From brain development to neurodegenerative diseases. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , <b>2020</b> , 1867, 118696	4.9	4
56	GSK-3-associated signaling is crucial to virus infection of cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , <b>2020</b> , 1867, 118767	4.9	4
55	Foreword: "Targeting signaling pathways in stem cells". <i>Advances in Biological Regulation</i> , <b>2014</b> , 56, 1-5	6.2	4
54	Activation of nonexpressed endogenous ecotropic murine leukemia virus by transfection of genomic DNA into embryo cells. <i>Journal of Virology</i> , <b>1983</b> , 45, 950-5	6.6	4
53	Recent advances in MDS mutation landscape: Splicing and signalling. <i>Advances in Biological Regulation</i> , <b>2020</b> , 75, 100673	6.2	4
52	GSK-3: a multifaceted player in acute leukemias. <i>Leukemia</i> , <b>2021</b> , 35, 1829-1842	10.7	4
51	Location-dependent role of phospholipase C signaling in the brain: Physiology and pathology. <i>Advances in Biological Regulation</i> , <b>2021</b> , 79, 100771	6.2	4
50	Where are we with understanding of COVID-19?. <i>Advances in Biological Regulation</i> , <b>2020</b> , 78, 100738	6.2	3
49	Microarray and pathway analysis reveals decreased CDC25A and increased CDC42 associated with slow growth of BCL2 overexpressing immortalized breast cell line. <i>Cell Cycle</i> , <b>2008</b> , 7, 3062-73	4.7	3

48	B-Raf and Insulin Synergistically Prevent Apoptosis and Induce Cell Cycle Progression in Hematopoietic Cell. <i>Cell Cycle</i> , <b>2004</b> , 3, 184-191	4.7	3
47	Subcellular Localization Relevance and Cancer-Associated Mechanisms of Diacylglycerol Kinases. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	3
46	Sensitivity of pancreatic cancer cells to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals can be regulated by WT-TP53. <i>Advances in Biological Regulation</i> , <b>2021</b> , 79, 100780	6.2	3
45	GSK3 as a Regulator of Cytoskeleton Architecture: Consequences for Health and Disease. <i>Cells</i> , <b>2021</b> , 10,	7.9	3
44	New perspectives in HCV therapy: entry inhibitors. <i>Recent Patents on Anti-infective Drug Discovery</i> , <b>2010</b> , 5, 181-94	1.6	2
43	Combining chemo-, hormonal and targeted therapies to treat breast cancer (Review). <i>Molecular Medicine Reports</i> , <b>2008</b> ,	2.9	2
42	Critical Roles of the Raf/MEK/ERK Pathway in Apoptosis and Drug Resistance <b>2006</b> , 101-134		2
41	Inositide-Dependent Nuclear Signalling in Health and Disease. <i>Handbook of Experimental Pharmacology</i> , <b>2020</b> , 259, 291-308	3.2	2
40	The NUPR1/p73 axis contributes to sorafenib resistance in hepatocellular carcinoma. <i>Cancer Letters</i> , <b>2021</b> , 519, 250-262	9.9	2
39	Current therapy and new drugs: a road to personalized treatment of myelodysplastic syndromes. <i>Expert Review of Precision Medicine and Drug Development</i> , <b>2018</b> , 3, 23-31	1.6	1
38	New Agents and Approaches for Targeting the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR Cell Survival Pathways <b>2013</b> , 331-372		1
37	No-Modified Saquinavir is Equally Efficient Against Doxorubicin Sensitive and Resistant Non-Small Cell Lung Carcinoma Cells / MODIFIKOVANA KOVANA FORMA SAKVINAVIRA EFIKASNO SU PRIMI RA RAST BLIJA NESITNOELIJSKOG KARCINOMA PLUÅ RAZLIITE OSETUIVOSTI NA DOXORUBICIN. <i>Journal of Medical Biochemistry</i> , <b>2018</b> , 22, 106-116	1.9	1
36	Role for Raf in the entry of viruses associated with AIDS (Review) <b>2004</b> , 25, 469		1
35	Comparative Gene Profiling of Acute Myeloid Leukemia (AML) and Malignant Melanoma (MEL) Cell Lines Exposed to the MEK Inhibitor PD0325901 Reveals Common Effectors of the MEK/ERK Kinase Module.. <i>Blood</i> , <b>2007</b> , 110, 3470-3470	2.2	1
34	PI-103, a Dual Inhibitor of Class IA Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin, Has Cytotoxic Activity in T-Cell Acute Lymphoblastic Leukemia Cells: A New Therapeutic Strategy in T-Cell Acute Lymphoblastic Leukemia.. <i>Blood</i> , <b>2008</b> , 112, 1921-1921	2.2	1
33	Role of PLCβ in the modulation of cell migration and cell invasion in glioblastoma. <i>Advances in Biological Regulation</i> , <b>2021</b> , 100838	6.2	1
32	The AKT Inhibitor, A443654, Induces Cell Cycle Arrest, Apoptosis and Synergizes with Chemotherapeutic Drugs in Multi-Drug Resistant T-Cell Acute Lymphoblastic Leukemia - A Novel Agent for Therapy of Drug Resistant ALL.. <i>Blood</i> , <b>2007</b> , 110, 3344-3344	2.2	1
31	GSK-3 in liver diseases: Friend or foe?. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , <b>2020</b> , 1867, 118743	4.9	1

30	Development of Mek inhibition (MEK-I)-Based Therapeutic Strategies in Acute Myeloid Leukemia (AML). <i>Blood</i> , <b>2008</b> , 112, 860-860	2.2	1
29	Where are we with understanding of COVID-19?. <i>Advances in Biological Regulation</i> , <b>2020</b> , 77, 100745	6.2	1
28	Phospholipase C beta1 (PI-PLCbeta1)/Cyclin D3/protein kinase C (PKC) alpha signaling modulation during iron-induced oxidative stress in myelodysplastic syndromes (MDS). <i>FASEB Journal</i> , <b>2020</b> , 34, 15400-15416	8.9	1
27	Lamin B1 Accumulation Effects on Autosomal Dominant Leukodystrophy (ADLD): Induction of Reactivity in the Astrocytes. <i>Cells</i> , <b>2021</b> , 10,	7.9	1
26	Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53.. <i>Cells</i> , <b>2022</b> , 11,	7.9	1
25	Pathobiology and Therapeutic Relevance of GSK-3 in Chronic Hematological Malignancies. <i>Cells</i> , <b>2022</b> , 11, 1812	7.9	1
24	Modulation of Raf/MEK/ERK kinase activity does not affect the chemoresistance profile of advanced prostate cancer cells <b>2005</b> , 26, 1637		0
23	Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines in the presence and absence of WT-TP53. <i>Advances in Biological Regulation</i> , <b>2021</b> , 100840	6.2	0
22	Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties.. <i>Aging</i> , <b>2022</b> , 14, 3365-3386	5.6	0
21	Raf/MEK/ERK Signaling <b>2015</b> , 275-305		
20	Upping the bid on engineered inducible cell death. <i>Cancer Biology and Therapy</i> , <b>2005</b> , 4, 537	4.6	
19	Enhanced ability of the progenipoiectin-1 to suppress apoptosis in human hematopoietic cells. <i>International Journal of Molecular Medicine</i> , <b>2002</b> , 10, 385	4.4	
18	Fibroblastic, hematopoietic, and hormone responsive epithelial cell lines and culture conditions for elucidation of signal transduction and drug resistance pathways by gene transfer. <i>Methods in Molecular Biology</i> , <b>2003</b> , 218, 185-201	1.4	
17	Elucidation of signal transduction pathways by transfection of cells with modified oncogenes. <i>Methods in Molecular Biology</i> , <b>2003</b> , 218, 203-20	1.4	
16	A Novel Ring-Substituted Diindolylmethane 1,1-bis [3?-(5-methoxyindolyl)]-1-(p-t-butylphenyl) Methane Abrogates ERK Activation and Induces Apoptosis in Acute Myeloid Leukemia (AML).. <i>Blood</i> , <b>2004</b> , 104, 3399-3399	2.2	
15	Key Roles of the Raf-1 and Akt in Drug Resistance, Cell Cycle Progression and the Prevention of Apoptosis in Hematopoietic Cells.. <i>Blood</i> , <b>2005</b> , 106, 1356-1356	2.2	
14	Role of BRAF Mutations in Hematopoietic Malignancies and the Induction of Cytokine-Independence-Synergy with PI3K/Akt Pathway.. <i>Blood</i> , <b>2005</b> , 106, 4291-4291	2.2	
13	Mutations of the Catalytic Subunit of Class IA PI3K Are Constitutively Active and Confer Factor-Independent Growth to Early Hematopoietic Cells.. <i>Blood</i> , <b>2006</b> , 108, 1455-1455	2.2	

- 12 Dominant Role of Raf/MEK/ERK Signaling in Hematopoietic Cell Cycle Progression, Prevention of Apoptosis and Drug Resistance.. *Blood*, **2006**, 108, 1116-1116 2.2
- 11 The Novel Akt Inhibitor Perifosine Induces Apoptosis, Cell Cycle Arrest and Synergizes with Chemotherapeutic Drugs in Acute Myelogenous Leukemia Cells by a JNK Dependent Mechanism - A Novel Therapeutic Approach for Leukemia Displaying Elevated Akt Signaling.. *Blood*, **2007**, 110, 3355-3355 2.2
- 10 Roles of Raf/MEK/ERK and PI3K/Akt/mTOR Pathways in Prevention of Apoptosis and Induction of Drug Resistance in Myeloid Hematopoietic Cells.. *Blood*, **2007**, 110, 641-641 2.2
- 9 Mutations in the Catalytic Subunit of Class IA PI3K Are Leukemogenic In Vivo.. *Blood*, **2007**, 110, 875-875 2.2
- 8 Targeting Survival Cascades Induced by Activation of Ras/Raf/MEK/ERK and PI3K/Akt Pathways to Sensitize Cancer Cells to Therapy **2008**, 81-114
- 7 Synergistic Proapoptotic Activity of Recombinant TRAIL Plus the Akt Inhibitor Perifosine in Acute Myelogenous Leukemia Cells-a Novel Therapeutic Approach for Leukemia Displaying Elevated Akt Signaling.. *Blood*, **2008**, 112, 957-957 2.2
- 6 Roles of Raf/MEK/ERK and PI3K/Akt/mTOR Signaling and p53 Pathways on Apoptosis, Drug Resistance and Therapeutic Sensitivity of Early Hematopoietic Precursor Cells. *Blood*, **2008**, 112, 503-503<sup>2,2</sup>
- 5 The Glycogensynthase Kinase 3b (GSK-3 $\beta$ ) Is Involved in Leukemic Transformation. *Blood*, **2008**, 112, 4489-4489 2.2
- 4 Erucylphosphocholine, the First Intravenously Applicable Alkylphosphocholine, Induces Cell Cycle Arrest, Apoptosis, and Synergizes with Chemotherapeutic Drugs in Acute Myelogenous Leukemia Cells-a Novel Therapeutic Approach for Leukemia.. *Blood*, **2008**, 112, 1330-1330 2.2
- 3 Parallel Signaling through PI3K/AKT/mTOR Mediates Resistance to MEK Inhibition in Preclinical Models of Acute Myeloid Leukemia (AML): Synergistic Effects of Combined MEK and mTOR Inhibition.. *Blood*, **2009**, 114, 594-594 2.2
- 2 Simultaneous Targeting of Bcl-2/Bcl-Xl and MEK/ERK Results in Highly Synergistic Induction of Apoptosis in Human AML, Both in Vitro and In Vivo.. *Blood*, **2009**, 114, 2757-2757 2.2
- 1 Dual Inhibition of Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin with NVP-BEZ235 as a New Therapeutic Option for T-Cell Acute Lymphoblastic Leukemia.. *Blood*, **2009**, 114, 2025-2025 2.2